These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10723309)

  • 21. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel uses for recombinant erythropoietin therapy in unlicensed indications.
    Macartney CA; Adgey AA; Jones FG; Morris TC; McMullin MF
    Hematol J; 2004; 5(2):181-5. PubMed ID: 15048070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress.
    Stenvinkel P; Bárány P
    Nephrol Dial Transplant; 2002; 17 Suppl 5():32-7. PubMed ID: 12091605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 26. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P; Pettersson E; Konarski-Svensson JK
    Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant erythropoietin in clinical practice.
    Ng T; Marx G; Littlewood T; Macdougall I
    Postgrad Med J; 2003 Jul; 79(933):367-76. PubMed ID: 12897214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
    Steffensen G; Aunsholt NA; Povlsen JV
    Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of anemia and secondary hyperparathyroidism with erythropoietin treatment in hemodialysis patients.
    Seyrek N; Paydas S; Sagliker Y
    Nephron; 1996; 73(2):338-9. PubMed ID: 8773378
    [No Abstract]   [Full Text] [Related]  

  • 33. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure.
    Ohyashiki JH; Fujieda H; Ohyashiki K; Toyama K
    Am J Hematol; 1991 Jun; 37(2):141-2. PubMed ID: 2069164
    [No Abstract]   [Full Text] [Related]  

  • 35. Anemia of chronic renal failure: treatment with erythropoietin.
    Navarro M; Alonso A; Avilla JM; Espinosa L
    Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment.
    Cetinkaya R; Odabas AR; Selcuk Y; Erman Z; Kaya H
    South Med J; 2003 May; 96(5):491-3. PubMed ID: 12911189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal disease. II. The clinical impact of recombinant human erythropoietin.
    Muirhead N
    J R Coll Physicians Lond; 1997; 31(2):125-30. PubMed ID: 9131506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin and its use in renal failure.
    Sulková S; Krajhanzl A
    EDTNA ERCA J; 1996; 22(1):suppl 1-7; quiz 8. PubMed ID: 10723310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.